Lung Cancer Genomic Screening Project for Individualized Medicine in Asia

Conditions

Non-small cell lung cancer

Mimura C, Takamiya R, Fujimoto S, Fukui T, Yatani A, Yamada J, Takayasu M, Takata N, Sato H, Fukuda K, Furukawa K, Hazama D, Katsurada N, Yamamoto M, Matsumoto S, Goto K, Tachihara M.

2024-04-173 citations

10.1186/s12885-024-12250-5

The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.

Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, Fukuhara T, Ikeda T, Yoh K, Kato T, Nishino K, Nakamura A, Nakachi I, Kuyama S, Furuya N, Sakakibara-Konishi J, Okamoto I, Taima K, Ebi N, Daga H, Yamasaki A, Kodani M, Udagawa H, Kirita K, Zenke Y, Nosaki K, Sugiyama E, Sakai T, Nakai T, Ishii G, Niho S, Ohtsu A, Kobayashi SS, Goto K.

2021-11-2456 citations

10.1038/s41586-021-04135-5

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients aged 16 years or older 2) Patients with pathologically (histology or cytology) confirmed non-small cell lung cancer 3) Patients with cancer of clinical stage II or higher, or postoperative recurrence 4) Patients who have not received any drug treatments or have a history of two or less drug regimens for lung cancer (Patients with a history of three or more drug regimens are not eligible. However, preoperative/postoperative adjuvant chemotherapy is not included in the calculation of the number of regimens) 5) Eastern Cooperative Oncology Group performance status (PS) of 0 or 1 6) Patients who meet the following criteria for major organ function (assessed by a test performed within 2 weeks prior to study enrollment): i) Neutrophil count : >=1500/mm3 ii) Hemoglobin : >=8.0 g/dl iii) Platelet count : >=7.5 x 104/mm3 iv) AST, ALT : <=ULN (upper limit of normal) x 2.5 (x 5 in patients with liver metastasis) v) Total bilirubin : <=ULN x 1.5 7) Patients without serious complications (e.g., interstitial pneumonitis, poorly controlled diabetes mellitus, cardiac disease, infection, etc.) 8) Patients who are expected to live for at least 3 months from the date of study enrollment 9) Patients who are able to submit samples that can be used for genetic analyses. The samples must be ones collected before the initial drug treatment 10) Patients who wish to enroll in genotype-directed clinical trials if the target gene alterations are identified in this study 11) Patients who have provided written consent to enroll in this study

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To characterize the clinicopathological and molecular biological features of lung cancer with genetic alterations identified in the genomic screening	—

Countries

Japan

Contacts

Public ContactMatsumoto Shingo

National Cancer Center Hospital East Department of Thoracic Oncology

shmatsum@east.ncc.go.jp04-7133-1111

Outcome results